These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32685911)

  • 1. Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes.
    Mistry J; Sharif M; Prideaux A; Smith C; Sumbwanyambe M; Sibley M; Carpenter L; Sweeney M; Kiely P
    Rheumatol Adv Pract; 2020; 4(2):rkaa013. PubMed ID: 32685911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.
    Nikiphorou E; Norton S; Young A; Carpenter L; Dixey J; Walsh DA; Kiely P;
    Ann Rheum Dis; 2016 Dec; 75(12):2080-2086. PubMed ID: 26979104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.
    Ledingham JM; Snowden N; Rivett A; Galloway J; Ide Z; Firth J; MacPhie E; Kandala N; Dennison EM; Rowe I
    Rheumatology (Oxford); 2017 Feb; 56(2):231-238. PubMed ID: 27694336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR.
    Melikoglu MA; Ataman S; Bodur H; Cay HF; Capkin E; Akgul O; Cevik R; Gogus F; Kamanli A; Yurdakul FG; Gurer G; Yagci I; Rezvani A; Duruoz MT; Sunar I
    Rheumatol Int; 2021 Nov; 41(11):1971-1978. PubMed ID: 34559275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID).
    Dougados M; Brault Y; Logeart I; van der Heijde D; Gossec L; Kvien T
    Arthritis Res Ther; 2012 May; 14(3):R129. PubMed ID: 22647431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis.
    Cheung PP; Lahiri M; March L; Gossec L
    Clin Rheumatol; 2017 May; 36(5):1149-1154. PubMed ID: 28039541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
    Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis.
    Salaffi F; Di Carlo M; Vojinovic J; Tincani A; Sulli A; Soldano S; Andreoli L; Dall'Ara F; Ionescu R; Simić Pašalić K; Balčune I; Ferraz-Amaro I; Tlustochowicz M; Butrimienė I; Punceviciene E; Toroptsova N; Grazio S; Morović-Vergles J; Masaryk P; Otsa K; Bernardes M; Boyadzhieva V; Cutolo M
    Joint Bone Spine; 2018 May; 85(3):317-322. PubMed ID: 28549945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data.
    Dougados M; Schmidely N; Le Bars M; Lafosse C; Schiff M; Smolen JS; Aletaha D; van Riel P; Wells G
    Ann Rheum Dis; 2009 Apr; 68(4):484-9. PubMed ID: 19074177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-quantitative analysis of
    Ravikanth R; Singh JK
    World J Nucl Med; 2020; 19(4):347-352. PubMed ID: 33623503
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO).
    Vojinovic J; Tincani A; Sulli A; Soldano S; Andreoli L; Dall'Ara F; Ionescu R; Pasalic KS; Balcune I; Ferraz-Amaro I; Tlustochowicz M; Butrimiene I; Punceviciene E; Toroptsova N; Grazio S; Morovic-Vergles J; Masaryk P; Otsa K; Bernardes M; Boyadzhieva V; Salaffi F; Cutolo M
    Autoimmun Rev; 2017 May; 16(5):548-554. PubMed ID: 28279841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis.
    Ter Wee MM; van Tuyl LH; Blomjous BS; Lems WF; Boers M; Terwee CB
    Arthritis Res Ther; 2016 Jan; 18():22. PubMed ID: 26794406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
    Pincus T; Swearingen CJ; Bergman M; Yazici Y
    J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study.
    Cai YM; Li R; Ye H; He J; Sun XL; Jin JY; Liu JJ; Gan YZ; You XJ; Xu J; Shi LJ; Cheng G; Wang QW; Li ZG
    Chin Med J (Engl); 2020 Jun; 133(12):1397-1403. PubMed ID: 32496302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
    Chandrashekara S; Priyanka BU
    Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients.
    Duarte C; Santos EJF; Ferreira RJO; Kvien TK; Dougados M; de Wit M; da Silva JAP; Gossec L
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33547229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.